CFMB (drug)

CFMB (drug)
Identifiers
	IUPAC name (2S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-phenyl-1,3-thiazol-2-yl)butanamide;
CAS Number	1208552-99-1;
PubChem CID	46226294;
ChemSpider	24656891;
ChEMBL	ChEMBL607315;
Chemical and physical data
Formula	C21H21ClN2OS
Molar mass	384.92 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)[C@@H](C1=CC=C(C=C1)Cl)C(=O)NC2=NC=C(S2)C3=CC=CC=C3;
	InChI InChI=1S/C21H21ClN2OS/c1-21(2,3)18(15-9-11-16(22)12-10-15)19(25)24-20-23-13-17(26-20)14-7-5-4-6-8-14/h4-13,18H,1-3H3,(H,23,24,25)/t18-/m0/s1; Key:ZVAPEFXSRDIMFP-SFHVURJKSA-N;

CFMB is an experimental drug which acts as a reasonably potent and selective agonist for the free fatty acid receptor FFAR2 (GPR43) with only weak activity at the closely related FFAR3 receptor. It has antiinflammatory effects and has been used to study the role of FFAR2 in regulation of gastrointestinal hormone release and immune system function.^[1]^[2]^[3]^[4]

References

^ Ang Z, Er JZ, Tan NS, Lu J, Liou YC, Grosse J, et al. (September 2016). "Human and mouse monocytes display distinct signalling and cytokine profiles upon stimulation with FFAR2/FFAR3 short-chain fatty acid receptor agonists". Scientific Reports. 6 34145. Bibcode:2016NatSR...634145A. doi:10.1038/srep34145. PMC 5036191. PMID 27667443.
^ Christiansen CB, Gabe MB, Svendsen B, Dragsted LO, Rosenkilde MM, Holst JJ (July 2018). "The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon". American Journal of Physiology. Gastrointestinal and Liver Physiology. 315 (1): G53 – G65. doi:10.1152/ajpgi.00346.2017. PMID 29494208.
^ Ørgaard A, Jepsen SL, Holst JJ (2019). "Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice". Islets. 11 (5): 103–111. doi:10.1080/19382014.2019.1587976. PMC 6773373. PMID 31469342.
^ Bartoszek A, Moo EV, Binienda A, Fabisiak A, Krajewska JB, Mosińska P, et al. (February 2020). "Free Fatty Acid Receptors as new potential therapeutic target in inflammatory bowel diseases". Pharmacological Research. 152 104604. doi:10.1016/j.phrs.2019.104604. PMID 31846762.

[1] Ang Z, Er JZ, Tan NS, Lu J, Liou YC, Grosse J, et al. (September 2016). "Human and mouse monocytes display distinct signalling and cytokine profiles upon stimulation with FFAR2/FFAR3 short-chain fatty acid receptor agonists". Scientific Reports. 6 34145. Bibcode:2016NatSR...634145A. doi:10.1038/srep34145. PMC 5036191. PMID 27667443.

[2] Christiansen CB, Gabe MB, Svendsen B, Dragsted LO, Rosenkilde MM, Holst JJ (July 2018). "The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon". American Journal of Physiology. Gastrointestinal and Liver Physiology. 315 (1): G53 – G65. doi:10.1152/ajpgi.00346.2017. PMID 29494208.

[3] Ørgaard A, Jepsen SL, Holst JJ (2019). "Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice". Islets. 11 (5): 103–111. doi:10.1080/19382014.2019.1587976. PMC 6773373. PMID 31469342.

[4] Bartoszek A, Moo EV, Binienda A, Fabisiak A, Krajewska JB, Mosińska P, et al. (February 2020). "Free Fatty Acid Receptors as new potential therapeutic target in inflammatory bowel diseases". Pharmacological Research. 152 104604. doi:10.1016/j.phrs.2019.104604. PMID 31846762.

[1]

[2]

[3]

[4]